Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102

by Professional Newco

MIN-102 is a selective PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept in multiple animal models. Phase I studi...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Los niños amamantados por mujeres inmun...

by Fundació Sant Joan de Déu

Las participantes del estudio son profesionales sanitarias de la organ...

Photos Stream